Search Results - "Sayed, Christopher J"

Criteria for Hidradenitis Suppurativa Competence Centers.

Authors: Marzano, Angelo V. Bechara, Falk G. Shi, Vivian Y. et al.

Source: Dermatology & Therapy. Jul2026, Vol. 16 Issue 7, p3445-3460. 16p.

Dual Targeted Therapy for Hidradenitis Suppurativa: A Narrative Review.

Authors: Kherallah, Kenan Chung, Claire S. Ghanshani, Raveena et al.

Source: Dermatology & Therapy. Jan2026, Vol. 16 Issue 1, p231-245. 15p.

Bimekizumab Pain Outcomes in Patients with Hidradenitis Suppurativa: Pooled 48-Week Results from BE HEARD I&II Phase 3 Randomized Clinical Trials.

Authors: Ingram, John R. Fujita, Hideki Gottlieb, Alice B. et al.

Source: Pain & Therapy. Dec2025, Vol. 14 Issue 6, p1861-1878. 18p.

Safety and efficacy of biologics in patients with Down syndrome and hidradenitis suppurativa: a retrospective cohort study.

Authors: Westerkam, Linnea L Santiago-Soltero, Karla Charrow, Alexandra et al.

Source: Clinical & Experimental Dermatology. Jul2025, Vol. 50 Issue 7, p1431-1433. 3p.

Concomitance of Hidradenitis Suppurativa and Porokeratoses.

Authors: SAYED, CHRISTOPHER J. EL-BEHAEDI, SALMA E. OSBORN, LINDSAY P. et al.

Source: Journal of Clinical & Aesthetic Dermatology. Apr2023, Vol. 16 Issue 4, p28-31. 4p.

A United States expert consensus to standardise definitions, follow‐up, and treatment targets for extra‐intestinal manifestations in inflammatory bowel disease.

Authors: Falloon, Katherine Cohen, Benjamin Ananthakrishnan, Ashwin N. et al.

Source: Alimentary Pharmacology & Therapeutics. May2022, Vol. 55 Issue 9, p1179-1191. 13p. 5 Charts.

Effect of Biologics on the Need for Procedural Interventions, Systemic Medications, and Healthcare Utilization in Patients with Hidradenitis Suppurativa: Real-World Data from the UNITE Registry.

Authors: Oliveira, Marília Rahawi, Kassim Duan, Yinghui et al.

Source: Dermatology & Therapy. Jul2023, Vol. 13 Issue 7, p1577-1585. 9p.

Social determinants of health and hidradenitis suppurativa disease severity: a geocoded analysis.

Authors: Shams, Rayad B McDaniel, Philip M Stitzenberg, Karyn B et al.

Source: Clinical & Experimental Dermatology. Jan2025, Vol. 50 Issue 1, p150-151. 2p.

PD‐L1 and LAG‐3 expression in advanced cutaneous squamous cell carcinomas.

Authors: Wu, Sam Slater, Nathaniel A. Sayed, Christopher J. et al.

Source: Journal of Cutaneous Pathology. Oct2020, Vol. 47 Issue 10, p882-887. 6p. 2 Color Photographs, 4 Charts.

A Hidradenitis Suppurativa molecular disease signature derived from patient samples by high-throughput RNA sequencing and re-analysis of previously reported transcriptomic data sets.

Authors: Freudenberg, Johannes M. Liu, Zhi Singh, Jennifer et al.

Source: PLoS ONE. 4/6/2023, Vol. 18 Issue 4, p1-15. 15p.

Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa.

Authors: SUN, NATALIE Z. RO, TERESA JOLLY, PUNEET et al.

Source: Journal of Clinical & Aesthetic Dermatology. Sep2017, Vol. 10 Issue 9, p36-38. 3p.

11th EHSF Conference 2022 Abstracts.

Source: Experimental Dermatology. Sep2022 Supplement S1, Vol. 31, p40-125. 86p.

Target molecules for future hidradenitis suppurativa treatment.

Authors: Zouboulis, Christos C. Frew, John W. Giamarellos‐Bourboulis, Evangelos J. et al.

Source: Experimental Dermatology. Jun2021 Supplement S1, Vol. 30, p8-17. 10p.

Dermatologist perceptions and preferences of laser hair reduction for hidradenitis suppurativa.

Authors: Mallela, Teja Wadhera, Akhil Sayed, Christopher J.

Source: Archives of dermatological research 7/12/2025; Vol. 317 (1).

Journal Info: Publisher: Springer Nature ISSN: 0340-3696